Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
e-PrEP: Telehealth for HIV PrEP in Black and Latino MSM
NCT05528653Phase 4Completed
- Sponsor
- AIDS Resource Center of Wisconsin
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by AIDS Resource Center of Wisconsin. Primary endpoint: Number and proportion of individuals who start PrEP at 18 months. Started Jul 2022; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05528653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528653.